Ambrx
Ambrx
Clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment.
About
What does Ambrx do?
Ambrx is a clinical-stage biopharmaceutical company that utilizes a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). Their technology allows for the incorporation of synthetic amino acids into proteins, enabling site-specific, homogenous, and stable conjugation. This platform aims to overcome limitations of traditional conjugation technologies and create precision biologics with optimized safety and efficacy for treating var…
What is Ambrx's revenue?
StartupHub estimates Ambrx's annual revenue at $35.7M (range $10.8M to $149.0M, 34% confidence), based on comparable companies in the sector.
What is Ambrx's valuation?
StartupHub estimates Ambrx's effective valuation at $1.6B (range $1.2B to $2.8B, 11% confidence), based on comparable companies in the sector.
How much funding has Ambrx raised?
Ambrx has raised a total of $462M in funding. The most recent round on record is ATM.
Where is Ambrx headquartered?
Ambrx is headquartered in San Diego, United States.
When was Ambrx founded?
Ambrx was founded in 2003.
What industry does Ambrx operate in?
Ambrx operates in Biotechnology, Drug Discovery, Oncology, Antibody-Drug Conjugates (ADCs), Precision Medicine, Synthetic Biology.
What is Ambrx's current status?
Ambrx's current operating status is: Inactive.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.